AR082189A1 - Formas de dosificacion gastrorretentivas, procedimiento - Google Patents
Formas de dosificacion gastrorretentivas, procedimientoInfo
- Publication number
- AR082189A1 AR082189A1 ARP110102414A ARP110102414A AR082189A1 AR 082189 A1 AR082189 A1 AR 082189A1 AR P110102414 A ARP110102414 A AR P110102414A AR P110102414 A ARP110102414 A AR P110102414A AR 082189 A1 AR082189 A1 AR 082189A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage form
- release
- opioid
- pharmaceutical dosage
- administration
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 10
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 5
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 230000000717 retained effect Effects 0.000 abstract 2
- 210000002784 stomach Anatomy 0.000 abstract 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 abstract 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 abstract 1
- LQJLLAOISDVBJM-FMKPAKJESA-N axomadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CC[C@@H](O)C2)CN(C)C)=C1 LQJLLAOISDVBJM-FMKPAKJESA-N 0.000 abstract 1
- 229950005531 axomadol Drugs 0.000 abstract 1
- 230000002051 biphasic effect Effects 0.000 abstract 1
- JIRYWFYYBBRJAN-ZFWWWQNUSA-N faxeladol Chemical compound CN(C)C[C@@H]1CCCC[C@H]1C1=CC=CC(O)=C1 JIRYWFYYBBRJAN-ZFWWWQNUSA-N 0.000 abstract 1
- 229950010643 faxeladol Drugs 0.000 abstract 1
- 229960002870 gabapentin Drugs 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- 229960002085 oxycodone Drugs 0.000 abstract 1
- 239000006069 physical mixture Substances 0.000 abstract 1
- 229920002689 polyvinyl acetate Polymers 0.000 abstract 1
- 239000011118 polyvinyl acetate Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 229960001233 pregabalin Drugs 0.000 abstract 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 abstract 1
- 229960005126 tapentadol Drugs 0.000 abstract 1
- 229960004380 tramadol Drugs 0.000 abstract 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Forma de dosificación farmacéutica gastrorretentiva que comprende una cantidad terapéuticamente efectiva de por lo menos un análogo de GABA, por lo menos un opioide, y por lo menos un excipiente farmacéuticamente aceptable, en la que dicha forma de dosificación resulta retenida en el estómago durante por lo menos cuatro horas y resulta adecuada para la administración de dos o una vez al día. Método de tratamiento de un trastorno mediante la administración en un paciente que lo necesita de una forma de dosificación que comprende una cantidad terapéuticamente efectiva de por lo menos un análogo de GABA, por lo menos un opioide, y por lo menos un excipiente farmacéuticamente aceptable, en la que dicha forma de dosificación resulta retenida en el estómago durante por lo menos cuatro horas y resulta adecuada para la administración de dos o una vez al día. Dicho opioide se encuentra en forma de liberación lenta o en forma de liberación inmediata.Reivindicación 4: Forma de dosificación farmacéutica según uno o más de las reivindicaciones 1 - 3, que comprende: a) un núcleo comprimido que comprende por lo menos dos capas de liberación, en el que una primera capa de liberación comprende por lo menos un análogo de GABA dispersado en una matriz de liberación lenta, y una segunda capa de liberación que comprende un opioide dispersado en una segunda matriz de liberación, b) por lo menos un saco de membrana permeable que comprende dicho núcleo, c) una capa encapsuladora y dicha forma de dosificación resulta adecuada para la administración de una o dos veces al día. Reivindicación 9: Forma de dosificación farmacéutica según uno o más de las reivindicaciones 1 a 8, en la que la liberación de análogo de GABA es bifásica. Reivindicación 10: Forma de dosificación farmacéutica según uno o más de las reivindicaciones 1 a 9, en la que la segunda capa de liberación comprende una mezcla física de acetato de polivinilo y polivinilpirrolidona. Reivindicación 17: Forma de dosificación farmacéutica según uno o más de las reivindicaciones 1 a 16, en la que dicho análogo de GABA es pregabalina, gabapentina y tiagabina, y el opioide es axomadol, morfina, oxicodona, tapentadol, faxeladol o tramadol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39904510P | 2010-07-06 | 2010-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082189A1 true AR082189A1 (es) | 2012-11-21 |
Family
ID=44503685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102414A AR082189A1 (es) | 2010-07-06 | 2011-07-06 | Formas de dosificacion gastrorretentivas, procedimiento |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20120009261A1 (es) |
| EP (1) | EP2590636A1 (es) |
| JP (3) | JP6005636B2 (es) |
| AR (1) | AR082189A1 (es) |
| AU (2) | AU2011276170B2 (es) |
| BR (1) | BR112013000190A2 (es) |
| CA (1) | CA2801620A1 (es) |
| MX (1) | MX2013000024A (es) |
| WO (1) | WO2012003968A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013000190A2 (pt) * | 2010-07-06 | 2017-11-07 | Gruenenthal Gmbh | formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide |
| EP2845625A1 (en) * | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
| JP2018520112A (ja) * | 2015-05-26 | 2018-07-26 | オディディ，イサ | 制御持続放出プレガバリン |
| JP7085473B2 (ja) | 2015-10-23 | 2022-06-16 | リンドラ セラピューティクス， インコーポレイティド | 治療薬の持続放出用の胃内滞留システム及びその使用方法 |
| CN108697649A (zh) | 2015-12-08 | 2018-10-23 | 林德拉有限公司 | 用于胃驻留系统的几何构型 |
| JP2019519487A (ja) | 2016-05-05 | 2019-07-11 | アクエスティブ セラピューティクス インコーポレイテッド | 送達増強エピネフリン組成物 |
| US20170290776A1 (en) * | 2016-05-05 | 2017-10-12 | Monosol Rx, Llc | Pharmaceutical compositions with enhanced permeation |
| WO2017205844A2 (en) | 2016-05-27 | 2017-11-30 | Lyndra, Inc. | Materials architecture for gastric residence systems |
| WO2018064630A1 (en) | 2016-09-30 | 2018-04-05 | Lyndra, Inc. | Gastric residence systems for sustained delivery of adamantane-class drugs |
| CA3066658A1 (en) | 2017-06-09 | 2018-12-13 | Lyndra, Inc. | Gastric residence systems with release rate-modulating films |
| JP7454262B2 (ja) * | 2018-08-28 | 2024-03-22 | エンタープライジズ インターナショナル インク | 耐湿性が強化された再パルプ化可能な紙帯およびその作成方法 |
| RS64394B1 (sr) | 2019-07-03 | 2023-08-31 | Alvogen Inc | Tablete pregabalina sa kontrolisanim otpuštanjem, postupak njihove proizvodnje i način upotrebe |
| EP4230199A4 (en) | 2020-12-04 | 2024-07-31 | Laboratorios Silanes S A De C V | COATED AND STABLE SOLID PHARMACEUTICAL COMPOSITION OF AN ANALGESIC AND AN ANTIEPILEPTIC AGAINST PAIN |
| WO2024086306A1 (en) * | 2022-10-19 | 2024-04-25 | Vitakey Inc. | Formulated food products |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3490742A (en) | 1966-01-14 | 1970-01-20 | Staley Mfg Co A E | Compressed tablets |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4034758A (en) | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4571333A (en) | 1983-06-14 | 1986-02-18 | Syntex (U.S.A.) Inc. | Controlled release naproxen and naproxen sodium tablets |
| GB8812490D0 (en) | 1988-05-26 | 1988-06-29 | Agricultural & Food Res | Delayed release formulations |
| US5071607A (en) | 1990-01-31 | 1991-12-10 | Alza Corporatino | Method and apparatus for forming a hole in a drug dispensing device |
| CA2041774C (en) | 1990-11-27 | 1994-04-19 | Mircea A. Mateescu | Use of cross-linked amylose as a matrix for the slow release of biologically active compounds |
| CA2032385A1 (en) | 1990-12-17 | 1992-06-18 | Chung Wai-Chiu | Enzymatically debranched starches as tablet excipients |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| KR100304997B1 (ko) | 1992-07-24 | 2002-04-24 | 드니랑글로아 | 효소에의해제어되는약물방출을위한가교결합된폴리하이드록실물질을포함하는정제 |
| US5616343A (en) | 1993-03-25 | 1997-04-01 | Labopharm, Inc. | Cross-linked amylose as a binder/disintegrant in tablets |
| SE9301057L (sv) | 1993-03-30 | 1994-10-01 | Pharmacia Ab | Beredning med kontrollerad frisättning |
| IL109460A (en) | 1993-05-10 | 1998-03-10 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
| DE4329794C2 (de) | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
| US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
| DE19630035A1 (de) | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| US6284273B1 (en) | 1998-02-24 | 2001-09-04 | Vincent Lenaerts | Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds |
| JP3199238B2 (ja) | 1998-09-18 | 2001-08-13 | 日本電気株式会社 | 符号分割多元接続方式における送信電力制御システム及び送信電力制御方法 |
| DE10029201A1 (de) * | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
| US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
| PT1190712E (pt) | 2000-09-22 | 2005-01-31 | Smb Technology | Composicao de esferas de tramadol para administracao oral uma vez por dia |
| US7858118B2 (en) | 2001-04-11 | 2010-12-28 | Galephar Pharmaceutical Research, Inc. | Extended release composition containing Tramadol |
| US20060159743A1 (en) | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US7612112B2 (en) * | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US7410965B2 (en) | 2002-05-29 | 2008-08-12 | Gruenenthal Gmbh | Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol |
| US20090317377A1 (en) * | 2005-08-26 | 2009-12-24 | Yeomans David C | Therapy procedure for drug delivery for trigeminal pain |
| NL2000281C2 (nl) * | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
| EP1976503A2 (en) * | 2005-12-29 | 2008-10-08 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| US8765178B2 (en) * | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| US10300031B2 (en) * | 2007-08-06 | 2019-05-28 | Trinity Laboratories Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| ES2619329T3 (es) | 2007-11-23 | 2017-06-26 | Grünenthal GmbH | Composiciones de tapentadol |
| KR101730924B1 (ko) | 2008-09-05 | 2017-04-27 | 그뤼넨탈 게엠베하 | 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물 |
| WO2011008298A2 (en) * | 2009-07-16 | 2011-01-20 | Nectid, Inc. | Novel axomadol dosage forms |
| BR112013000190A2 (pt) * | 2010-07-06 | 2017-11-07 | Gruenenthal Gmbh | formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide |
-
2011
- 2011-07-06 BR BR112013000190A patent/BR112013000190A2/pt not_active Application Discontinuation
- 2011-07-06 MX MX2013000024A patent/MX2013000024A/es not_active Application Discontinuation
- 2011-07-06 JP JP2013517102A patent/JP6005636B2/ja not_active Expired - Fee Related
- 2011-07-06 AU AU2011276170A patent/AU2011276170B2/en not_active Ceased
- 2011-07-06 US US13/176,798 patent/US20120009261A1/en not_active Abandoned
- 2011-07-06 CA CA2801620A patent/CA2801620A1/en not_active Abandoned
- 2011-07-06 EP EP11746440.4A patent/EP2590636A1/en not_active Withdrawn
- 2011-07-06 WO PCT/EP2011/003343 patent/WO2012003968A1/en active Application Filing
- 2011-07-06 AR ARP110102414A patent/AR082189A1/es unknown
-
2016
- 2016-05-30 AU AU2016203567A patent/AU2016203567B2/en not_active Ceased
- 2016-09-06 JP JP2016173316A patent/JP6294420B2/ja not_active Expired - Fee Related
- 2016-12-13 US US15/377,363 patent/US20170119663A1/en not_active Abandoned
-
2018
- 2018-02-14 JP JP2018023944A patent/JP6550157B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016203567B2 (en) | 2017-12-07 |
| JP2018109027A (ja) | 2018-07-12 |
| CA2801620A1 (en) | 2012-01-12 |
| BR112013000190A2 (pt) | 2017-11-07 |
| US20170119663A1 (en) | 2017-05-04 |
| AU2016203567A1 (en) | 2016-06-16 |
| EP2590636A1 (en) | 2013-05-15 |
| JP2013530193A (ja) | 2013-07-25 |
| JP2017039726A (ja) | 2017-02-23 |
| JP6005636B2 (ja) | 2016-10-12 |
| WO2012003968A1 (en) | 2012-01-12 |
| MX2013000024A (es) | 2013-02-01 |
| AU2011276170B2 (en) | 2016-03-10 |
| JP6550157B2 (ja) | 2019-07-24 |
| AU2011276170A1 (en) | 2012-12-06 |
| US20120009261A1 (en) | 2012-01-12 |
| JP6294420B2 (ja) | 2018-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082189A1 (es) | Formas de dosificacion gastrorretentivas, procedimiento | |
| AR082167A1 (es) | Formas de dosificacion gastrorretentivas | |
| AR056824A1 (es) | Tableta de neramexano con matriz de liberacion modificada | |
| MX2009005339A (es) | Suspensiones analgesicas de liberacion modificada. | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| UY29759A1 (es) | Formulaciones de ibandronato mejoradas | |
| MX2009013574A (es) | Formas de dosificacion solidas o semisolidas de liberacion modificada. | |
| AR099078A2 (es) | Un medicamento que comprende acetato de glatiramer | |
| AR124500A2 (es) | Aumento de la biodisponibilidad de droga en terapia naltrexona | |
| JP2012501973A5 (es) | ||
| EA201100305A1 (ru) | Лечение респираторных заболеваний | |
| AR087744A1 (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa | |
| JP2013541583A5 (es) | ||
| ATE539747T1 (de) | Verfahren und medikamente zur verabreichung von ibuprofen | |
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| FI2683245T4 (fi) | Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä | |
| AR052062A1 (es) | Composicion y metodo para tratar el asma | |
| UY31826A (es) | Compuesto peptídico y su uso | |
| RU2012129839A (ru) | Комбинация теобромина с деконгестантом и ее применение для лечения кашля | |
| AR077123A1 (es) | Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica | |
| JP2016515137A5 (es) | ||
| CO6410284A2 (es) | Composición farmacéutica oral para uso en enfermedades respiratorias | |
| JP2011513315A5 (es) | ||
| CO6592037A2 (es) | Combinación de un aine y un aminoacido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |